December 10, 2021
Sumitomo Dainippon Pharma said on December 9 that the US Patent and Trademark Office (USPTO) has handed down its decision that all claims over the methods of use patent related to its atypical antipsychotic Latuda (lurasidone) are unpatentable. The court...read more